DIMERIX LIMITED — Investor Presentation 2014

Sep 10, 2014

==> picture [252 x 89] intentionally omitted <==

Diversified Biotechnology Company

Anton Uvarov PhD Executive Director Investor Presentation September 2014

==> picture [210 x 272] intentionally omitted <==

Important information

==> picture [74 x 75] intentionally omitted <==

This presentation has been prepared by Sun Biomedical Limited. (“Sun Biomedical” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision.

This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Sun Biomedical, nor does it constitute financial product advice or take into account any individual’s investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Sun Biomedical and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Sun Biomedical is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Sun Biomedical securities.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Sun Biomedical, its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

The information presented in this presentation is subject to change without notice and Sun Biomedical does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation.

The distribution of this presentation may be restricted by law and you should observe any such restrictions.

Forward looking statements

This presentation contains certain forward looking statements that are based on the Company’s management’s beliefs, assumptions and expectations and on information currently available to management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Sun Biomedical to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the political and economic environment in which Sun Biomedical will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. To the full extent permitted by law, Sun Biomedical and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).

==> picture [92 x 33] intentionally omitted <==

Company Overview After Capital Raising

Corporate Overview	Corporate Overview
ASX Code:	SBN
Share Price:	$0.01
Market cap:	$4.1m
Cash:	$1.8m
Shares on issue:	413.6m
Options:	20.9m
Board of Directors
Mr Howard Digby	Former senior roles at IBM,
Executive Chairman	Adobe, Gartner and the
	Economist Group, currently
	Non-Executive Director of
	Cynata Therapeutics
Dr Anton Uvarov	Former Healthcare Equities
Executive Director	Analyst at Citigroup (US),
	currently Non-Executive
	Director of Actinogen Limited
Mr Evan Cross	Currently Executive Director of
Non-Executive Director	Greenday Corporate
Mr Peter Webse	Currently Managing Director of
Non-Executive Director	Platinum Corporate Secretariat,
	Non-Executive Director of
	Cynata Therapeutics

==> picture [92 x 33] intentionally omitted <==

Sun Biomedical Product Pipeline

==> picture [56 x 66] intentionally omitted <==

New Therapeutics and Diagnostics for Asthma

Proof-of-Concept Pre-Clinical Stage Clinical Stage Product launch SBN-01 (in partnership with Telethon Kids) Oraline® Family - Workplace and personal saliva testing solutions Product Design Prototype Validation Manufacturing Product launch (Market Ready) Oraline ®4 (standard Strip) Oraline ® 6 (new IP, dual Strip)

==> picture [92 x 33] intentionally omitted <==

New Research Collaboration in Asthma

World Leading Institution as Research Partner

Study Objective

==> picture [108 x 107] intentionally omitted <==

==> picture [56 x 66] intentionally omitted <==

• i. To identify genes which have potential utility as a diagnostic and/or therapeutic target that are predictive of asthma

• ii. To perform a detailed study of immune responses to house dust mite in allergic subjects with or without asthma, to determine if there is a specific pattern of immune responses associated with asthma

Two Stage Study Design

• i. The discovery cohort will consist of 15 house dust mite allergic subjects with asthma and 15 house dust allergic subjects without asthma.

• ii. The validation cohort will consist of another 30 house dust mite allergic subjects (15 with asthma and 15 without asthma)

Study Completion – YE2015

==> picture [92 x 33] intentionally omitted <==

Asthma – Huge Medical Need

==> picture [56 x 66] intentionally omitted <==

• ⊚ The cause not really known, though clear links to both genetics (family history) and environment

• ⊚ In an asthmatic person, the muscles of the bronchial tubes tighten and thicken, and the air passages become inflamed and mucus-filled, making it difficult for air to move

• ⊚ According to WHO estimates, 235 million people suffer from asthma with 59% having uncontrolled disease

• ⊚ Asthma is the most common chronic disease among children

• ⊚ Asthma is under-diagnosed and under-treated, creating a substantial burden to individuals and families

==> picture [326 x 298] intentionally omitted <==

==> picture [92 x 33] intentionally omitted <==

Asthma – Large Commercial Opportunity

==> picture [56 x 66] intentionally omitted <==

• ⊚ Asthma and related respiratory disease will be the third largest global therapeutic categories, with $41B - $46B in combined sales

• ⊚ As the industry looks to the future, this growing market represent an opportunity for manufacturers to introduce novel molecules, new combinations and innovative delivery devices to help better treat patients.

• ⊚ Most widely-used asthma medicines today employ a molecule that has long since lost patent protection, instead relying on unique, patented delivery devices

• ⊚ New first-in-class molecules could challenge top selling brands like Advair ($5B+ in sales) and Singulair (~$4B in sales)

Source: IMS Healthcare

==> picture [92 x 33] intentionally omitted <==

The Importance of the Proof-of-Concept Study

==> picture [56 x 66] intentionally omitted <==

House Dust Mite (HDM) allergy is a significant risk factor for asthma in many countries

Allergic sensitization induced by exogenous allergenic molecules (HDM allergens) is the result of exposure of organs of the human body to such molecules. In this interplay, intrinsic properties of the exogenous proteins and environmental cofactors certainly play a role, but host-immune factors are of crucial importance to explain why every individual exposed to such an allergen does not develop an . allergy

Predisposition for developing allergy is the result of a complex multifactorial interplay of genes and environment. To understand the immunobiological mechanism of sensitization to allergens, their interaction with relevant structural and immune cells during mucosal exposure and entry, is of the utmost importance. Understanding could lead to development of novel therapies with disease modifying potential.

==> picture [296 x 346] intentionally omitted <==

==> picture [92 x 33] intentionally omitted <==

Drugs of Abuse (Saliva Test) – Market Opportunity

==> picture [56 x 66] intentionally omitted <==

==> picture [361 x 217] intentionally omitted <==

----- Start of picture text -----

Source: BCC Research
----- End of picture text -----

• ⊚ The global market for DOA testing during past 5 years showed compound annual growth rate (CAGR) of 4.6%. It is expected to reach $2.6 billion in 2014 and $3.4B by 2018

• ⊚ The U.S. testing market segment generated the largest share of revenues in the previous 5 years and is expected to reach $2.0 billion in 2014, with a CAGR of 5.2%

• ⊚ The European Union had the second largest market segment and is expected to reach $446 million in 2014, with a CAGR of 2.9%

• ⊚ In Australia a campaign by unions to end urine testing of employees to detect alcohol and drug use recently had another win with the Fair Work Commission declaring workers at a state-owned energy company are to be tested using saliva test

==> picture [92 x 33] intentionally omitted <==

Oraline ® Product Family

==> picture [56 x 66] intentionally omitted <==

⊚ Oraline ® 4

• unique cap collection mechanism

• prototype developed and initial product run completed

• NATA approved laboratory tests of Oraline®4 completed in 1H2014

• Further tuning of the test strips within the device is currently ongoing with existing and new manufacturers

==> picture [296 x 147] intentionally omitted <==

⊚ Oraline ® 6 (dual strip)

• dual strip mechanism for better accuracy

• • SUN Biomedical acquired drawings and design documentation in 1H2014

• ability to detect up to six drug substances

• • currently planning prototype development and first tests for Oraline ®6

==> picture [296 x 147] intentionally omitted <==

==> picture [92 x 33] intentionally omitted <==

Sun Biomedical – Intellectual Property

==> picture [56 x 66] intentionally omitted <==

US Patent Number	Description
6046058	Colour Coded Test Strip
5962336	Multi-Test Panels
6372516	Lateral Flow Test Devices
7041253	Sample Collection and Test Device
7300627	Test Sample Collection System

==> picture [92 x 33] intentionally omitted <==

Investment Highlights and Key Value Drivers

==> picture [56 x 66] intentionally omitted <==

• ⊚ Experienced management and board dedicated towards building the company and product pipeline in lean approach

• ⊚ Investment in new technologies and intellectual property based on extensive research and market analysis

• ⊚ Focus on products with high unmet need and defined regulatory pathway

• ⊙ Oraline®4 strip fine tuning to be completed

• ⊙ Oraline®4 product validation with NATA certified laboratory

• ⊙ Oraline®4 product launch

• ⊙ Oraline®6 prototype development and first tests to be completed

• ⊙ Oraline®6 product validation with NATA certified laboratory

• ⊙ Oraline®6 product launch

• ⊙ Distribution agreements and licensing to third parties for Oraline® product family

• ⊙ Proof-of-concept study results to identify new genes and immune response mechanisms to house dust mites in asthmatic subjects

• ⊙ Acquisition of new technologies in the respiratory therapeutic category

==> picture [92 x 33] intentionally omitted <==